Landscapes / Targets
CD38
14 drugs act on CD38, in 63 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs14
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Approved | 26 Feb 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 26 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Multiple Myeloma, Amyloidosis and 2 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 1 Apr 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 1 Apr 2027 · Phase 2 trial completes | ||||
| Also tested for | Plasma Cell Myeloma, Plasma Cell Myeloma Refractory and 2 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | 1 Dec 2026soonPhase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 1 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Antibody-mediated Rejection, Microvascular Inflammation and 5 more | ||||
| Open drug page | |||||
— |
Phase 3 | Mar 2027Phase 2 trial completes | |||
| Next date | Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Primary Immune Thrombocytopenia, Systemic Lupus Erythematosus and 4 more | ||||
| Open drug page | |||||
— |
Sinocelltech · Public 688520.SS |
Phase 3 | Apr 2027Phase 1/2 trial completes | ||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed or Refractory Hematologic Malignancies, IgA Nephropathy and 3 more | ||||
| Open drug page | |||||
— |
Phase 3 | 2 Jul 2027Phase 3 trial completes | |||
| Next date | 2 Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Influenza | ||||
| Open drug page | |||||
— |
Henlius · Public 2696.HK |
Phase 3 | Jul 2027Phase 3 trial completes | ||
| Next date | Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Newly Diagnosed Multiple Myeloma, Multiple Myeloma (MM) | ||||
| Open drug page | |||||
— |
Phase 3 | Nov 2027Phase 2 trial completes | |||
| Next date | Nov 2027 · Phase 2 trial completes | ||||
| Also tested for | Multiple Myeloma, Relapsed or Refractory Multiple Myeloma and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | 16 Mar 2028Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 16 Mar 2028 · Phase 3 trial completes | ||||
| Also tested for | Immune Thrombocytopenic Purpura (ITP), Kidney Disease and 1 more | ||||
| Open drug page | |||||
F182112not checked |
— |
Phase 3 | 20 May 2028Phase 2 trial completes | ||
| Next date | 20 May 2028 · Phase 2 trial completes | ||||
| Also tested for | Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM) and 1 more | ||||
| Open drug page | |||||
— |
Zhejiang ACEA Pharmaceutical +1 |
Phase 1/2 | 31 Dec 2026Phase 1/2 trial completes | ||
| Next date | 31 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed or Refractory Multiple Myeloma | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and 5 more | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Nov 2028Phase 2 trial completes | |||
| Next date | 30 Nov 2028 · Phase 2 trial completes | ||||
| Also tested for | Chronic Immune Thrombocytopenia, Antibody Mediated Rejection | ||||
| Open drug page | |||||
— |
Phase 1 | Jul 2027Phase 1 trial completes | |||
| Next date | Jul 2027 · Phase 1 trial completes | ||||
| Also tested for | Relapsed/Refractory Multiple Myeloma | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 13 of 14 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026